rs143418001
Positions:
Variant summary
Our verdict is Benign. Variant got -15 ACMG points: 0P and 15B. BP4_ModerateBP6_Very_StrongBP7BS2
The NM_171998.4(RAB39B):āc.93T>Cā(p.Gly31=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000033 in 1,210,496 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 11 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā ā ).
Frequency
Genomes: š 0.00021 ( 0 hom., 6 hem., cov: 24)
Exomes š: 0.000015 ( 0 hom. 5 hem. )
Consequence
RAB39B
NM_171998.4 synonymous
NM_171998.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.379
Genes affected
RAB39B (HGNC:16499): (RAB39B, member RAS oncogene family) This gene encodes a member of the Rab family of proteins. Rab proteins are small GTPases that are involved in vesicular trafficking. Mutations in this gene are associated with X-linked cognitive disability. [provided by RefSeq, Aug 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -15 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.35).
BP6
Variant X-155264196-A-G is Benign according to our data. Variant chrX-155264196-A-G is described in ClinVar as [Likely_benign]. Clinvar id is 436460.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.379 with no splicing effect.
BS2
High Hemizygotes in GnomAd4 at 6 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAB39B | NM_171998.4 | c.93T>C | p.Gly31= | synonymous_variant | 1/2 | ENST00000369454.4 | NP_741995.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAB39B | ENST00000369454.4 | c.93T>C | p.Gly31= | synonymous_variant | 1/2 | 1 | NM_171998.4 | ENSP00000358466 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000205 AC: 23AN: 112394Hom.: 0 Cov.: 24 AF XY: 0.000145 AC XY: 5AN XY: 34580
GnomAD3 genomes
AF:
AC:
23
AN:
112394
Hom.:
Cov.:
24
AF XY:
AC XY:
5
AN XY:
34580
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000491 AC: 9AN: 183454Hom.: 0 AF XY: 0.0000589 AC XY: 4AN XY: 67894
GnomAD3 exomes
AF:
AC:
9
AN:
183454
Hom.:
AF XY:
AC XY:
4
AN XY:
67894
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000146 AC: 16AN: 1098049Hom.: 0 Cov.: 30 AF XY: 0.0000138 AC XY: 5AN XY: 363405
GnomAD4 exome
AF:
AC:
16
AN:
1098049
Hom.:
Cov.:
30
AF XY:
AC XY:
5
AN XY:
363405
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000213 AC: 24AN: 112447Hom.: 0 Cov.: 24 AF XY: 0.000173 AC XY: 6AN XY: 34643
GnomAD4 genome
AF:
AC:
24
AN:
112447
Hom.:
Cov.:
24
AF XY:
AC XY:
6
AN XY:
34643
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jan 22, 2016 | - - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | May 30, 2019 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 22, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at